This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Niwano, Y.
Right arrow Articles by Yamaguchi, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Niwano, Y.
Right arrow Articles by Yamaguchi, H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 1998, p. 967-970, Vol. 42, No. 4
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

In Vitro and In Vivo Antidermatophyte Activities of NND-502, a Novel Optically Active Imidazole Antimycotic Agent

Yoshimi Niwano,1,* Naoki Kuzuhara,1 Hiroki Kodama,1 Masanori Yoshida,1 Tsuneo Miyazaki,1 and Hideyo Yamaguchi2

Research Center, Nihon Nohyaku Co., Ltd., Kawachinagano, Osaka 586,1 and Teikyo University Institute of Medical Mycology, 359 Otsuka, Hachioji, Tokyo 192-03,2 Japan

Received 5 November 1997/Returned for modification 18 December 1997/Accepted 2 February 1998

In vitro and in vivo antidermatophyte activities of NND-502, a new imidazole antimycotic agent, were compared with those of two existing antifungal agents, lanoconazole and terbinafine. NND-502 exhibited strong in vitro antifungal activity against Trichophyton spp.; its MIC was 1 to 4 times lower than that of lanoconazole or terbinafine. In an in vivo study with a guinea pig model of tinea pedis, 7-day topical treatment with a 0.5% solution of NND-502 (dissolved in polyethylene glycol 400) was more effective than that with a 0.5% solution of either lanoconazole or terbinafine for eradicating fungi from the infected feet. When the duration of treatment was shortened to 3 days, a topical 1% solution of NND-502 achieved a complete mycological cure, while topical 1% solutions of lanoconazole and terbinafine did not.

* Corresponding author. Mailing address: Yoshimi Niwano, Research Center, Nihon Nohyaku Co., Ltd., 345 Oyamadacho, Kawachinagano, Osaka 586, Japan. Phone: 0721-56-9000. Fax: 0721-56-1622. E-mail: mntoxlab{at}os.luice.or.jp.

Antimicrobial Agents and Chemotherapy, April 1998, p. 967-970, Vol. 42, No. 4
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Tatsumi, Y., Yokoo, M., Arika, T., Yamaguchi, H. (2001). In Vitro Antifungal Activity of KP-103, a Novel Triazole Derivative, and Its Therapeutic Efficacy against Experimental Plantar Tinea Pedis and Cutaneous Candidiasis in Guinea Pigs. Antimicrob. Agents Chemother. 45: 1493-1499 [Abstract] [Full Text]  
  • Furukawa, K., Sasaki, H., Pollard, R. B., Suzuki, F. (2000). Lanoconazole, a new imidazole antimycotic compound, protects MAIDS mice against encephalitis caused by Cryptococcus neoformans. J Antimicrob Chemother 46: 443-450 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»